About this trial

Electrocardiogram (ECG) Q-T prolongation is a cardiac electrophysiological disorder associated with the occurrence of arrhythmias potentially fatal. Several psychotropic drugs are associated with an increased risk of QT prolongation, which is why in clinical practice a baseline ECG is performed before a psychotropic drug is prescribed. However, there are no validated protocols establishing when to repeat this examination or describing clinical events when this examination should be repeated in clinical follow-up.

The study aims to investigate the incidence of QTc prolongation events as a side effect of chronic psychotropic drug administration. For this purpose, ECGs will be recorded and confounding factors of patients at the beginning of psychotropic therapy and after 3, 6 and 12 months will be analyzed.

Eligibility criteria

Qualifiers

Admitted to psychiatry ward

Starting a psychotropic drug acting on QT interval

Disqualifiers

Age >18aa

History of administration of drug acting on QT interval in the 3 months prior

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

100 Participants
are grouped into 3 trial groups

Locations

6
Neuropsichiatria Infantile, IRCCS - OC Associazione Oasi Maria SS. ONLUS94018, TroinaEnna, Italy
AOU Meyer IRCCS50139, FlorenceFI, Italy
IRCCS Fondazione Stella Maris56128, CalambronePisa, Italy
Neuropsichiatria infantile, Policlinico S.Orsola-Malpighi40138, Bologna Italy

Sponsors and collaborators

Meyer Children's Hospital IRCCS

Lead sponsor